Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drug-target Mendelian randomization revealed a significant association of genetically proxied metformin effects with increased prostate cancer risk.

Molecular carcinogenesis - 1 May 2024

Sun Xiaohui, Ping Jie, Guo Xingyi, Long Jirong, Cai Qiuyin, Shu Xiao-Ou, Shu Xiang

Abstract excerpt

The association between metformin use and risk of prostate cancer remains controversial, while data from randomized trials is lacking. We aim to evaluate the association of genetically proxied metformin effects with prostate cancer risk using a drug-target Mendelian randomization (MR) approach. Summary statistics for prostate cancer were obtained from the Prostate Cancer Association Group to Investigate Cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Diabetes Mellitus, Type 2
Share to Genome-Wide Association Study

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mendelian Randomization Analysis

Share to Metformin

Share to Polymorphism, Single Nucleotide

Share to Prostatic Neoplasms

Share to Testosterone

Source

Open in PubMed Open full text

Identifiers

PMID: 38517045
DOI: 10.1002/mc.23692
PMCID: PMC11014764

Genes

APH1A
NDUFA13

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug-target Mendelian randomization revealed a significant association of genetically proxied metformin effects with increased prostate cancer risk.PMID 38517045Read ↗

Genetically-proxied anti-diabetic drug target perturbation and risk of cancer: a Mendelian randomization analysisSemantic proximity Read ↗

Evaluating the Impact of Putative Metformin Targets on Cancer Outcomes: A Drug-Target Mendelian Randomization Study.Semantic proximity Read ↗

Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis.Semantic proximity Read ↗

Genetically proxied PCSK9 inhibition provides indication of lower prostate cancer risk: a Mendelian randomization studySemantic proximity Read ↗

Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study.Semantic proximity Read ↗

Association between metformin medication, genetic variation and prostate cancer risk.Semantic proximity Read ↗

Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancers: A mendelian randomization analysis.Semantic proximity Read ↗

Genetically Proxied Therapeutic Effect of Metformin Use, Blood Pressure, and Hypertension's Risk: a Drug Target-Based Mendelian Randomization Study.Semantic proximity Read ↗

A Mendelian randomization study between metabolic syndrome and its components with prostate cancer.Semantic proximity Read ↗

Metformin treatment and reduction of gastrointestinal cancer risk: A 2-sample Mendelian randomization study.Semantic proximity Read ↗

Mendelian randomization revealing the protective effect of sodium-glucose cotransporter 2 inhibition on prostate cancer with verified evidence from electronic healthcare and biological dataSemantic proximity Read ↗

Genetically-proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.